About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Tennessee | 343 Studies

Clinical Trials MelanomaTennessee

Melanoma Clinical Trials in Tennessee

Find 343 clinical trials for melanoma near Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 81-100 of 343 trials

CompletedA Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionThe purpose of this study is to assess the safety and tolerability of subcutaneous nivolumab vs intravenous nivolumab in participants with completely resected Stage IIIA/B/C/D or…NCT05297565·Fort Wayne, Indiana and 15 others CompletedA Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsThe purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)…NCT05668585·Tucson, Arizona and 25 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingFamilial Investigations of Childhood Cancer PredispositionNOTE: This is a research study and is not meant to be a substitute for clinical genetic testing.NCT03050268·Memphis, Tennessee

CompletedA Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid TumorsProtocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of…NCT02573259·Los Angeles, California and 66 others

Active not recruitingADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.NCT04044859·Orlando, Florida and 16 others

Active not recruitingA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryThis study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called…NCT05608291·La Jolla, California and 210 others

CompletedGlycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.NCT05259696·La Jolla, California and 12 others

CompletedA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for…NCT00600496·Detroit, Michigan and 3 others

CompletedA Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaThe purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage…NCT00289627·Little Rock, Arkansas and 52 others

CompletedA Study of INCAGN01876 in Participants With Advanced or Metastatic Solid TumorsThis was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts.NCT02697591·Los Angeles, California and 7 others

RecruitingA Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic InformationThis phase II trial compares the effect of using risk-based stratification to guide surgical management to the usual approach in treating cutaneous melanoma, atypical…NCT07621614·Oakland, California and 12 others

TerminatedBlood Sample Collection to Evaluate Biomarkers in Subjects With Untreated MelanomaThe primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay…NCT03727087·Little Rock, Arkansas and 35 others

RecruitingAssessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsThis is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are…NCT06418204·Fairbanks, Alaska and 490 others

RecruitingSafety and Tolerability Study of GIM-531 in Advanced Solid TumorsGIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy.NCT06425926·Scottsdale, Arizona and 10 others

CompletedSafety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted VaccineIn this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors.NCT03633110·La Jolla, California and 10 others

AvailableExpanded Access Program of AMTAGVI That is Out of Specification for Commercial ReleaseThe objective of this expanded access protocol is to provide access to Out Of Specification (OOS) AMTAGVI treatment to patients.NCT05398640·Gilbert, Arizona and 47 others

TerminatedStudy CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung…NCT02771626·Scottsdale, Arizona and 16 others

CompletedCD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabThis study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with…NCT03123783·Tucson, Arizona and 22 others

CompletedSU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaThe purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region.NCT00577382·Boston, Massachusetts and 4 others

TerminatedPhase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaThe purpose of the study is to comply with the Pediatric Investigation Plan requirements of IpilimumabNCT01696045·Phoenix, Arizona and 31 others

PreviousPage 5 of 18Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma